BALTIMORE, July 9, 2018 – Elixirgen Therapeutics, Inc. raised $4 million in a Series A funding round from University of Tokyo Edge Capital (UTEC).
Elixirgen Therapeutics, Inc. is a biotechnology company founded by Minoru Ko, M.D., Ph.D., that is focused on curing humanity’s ailments through innovations in stem cell biology. Elixirgen Therapeutics is pursuing cures using the ZSCAN4 gene, which was originally identified by Dr. Ko’s lab at the National Institute on Aging (NIA, a division of the National Institutes of Health, NIH). Its current lead candidate is EXG-34217, a therapy that uses the ZSCAN4 gene to treat people with telomere shortening diseases such as Dyskeratosis Congenita. The company is on track to filing an IND application and beginning clinical trials for its lead candidate in 2019.
Elixirgen Therapeutics is pleased to begin a professional relationship with UTEC and is looking forward to working with the “co-founders for innovation.” The company will be counting on UTEC’s vast network of connections and their experience in improving businesses at all stages of development. With the help of UTEC, Elixirgen Therapeutics will send its first therapy into clinical trials and will take major leaps toward making treatments available to the people who need them.
This news was featured in the Baltimore Business Journal.